Nateglinide

From Wikipedia, the free encyclopedia

Nateglinide
Systematic (IUPAC) name
3-phenyl-2-(4-propan-2-ylcyclohexyl) carbonylamino-propanoic acid
Identifiers
CAS number	105816-04-4
ATC code	A10BX03
PubChem	60026
DrugBank	APRD00593
Chemical data
Formula	C19H27NO3
Mol. weight	317.423 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	98%
Metabolism	?
Half life	1.5 hours
Excretion	?
Therapeutic considerations
Licence data	EU US
Pregnancy cat.	?
Legal status
Routes	?

Nateglinide (INN, trade name Starlix®) is a drug for the treatment of type 2 diabetes.

Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs and is sold by Novartis.

[edit] Pharmacology

Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the beta cells. This depolarizes the beta cells, opening the cells' calcium channels, and the resulting calcium influx induces insulin secretion.

[edit] Dosage

Nateglinide is delivered in tablet form.

[edit] External links

• Starlix - website of the manufacturer.
• How Nateglinide Works - website of the manufacturer.

Oral antidiabetic drugs (A10B) edit
Biguanides:	Metformin
Sulfonylureas:	Chlorpropamide, glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide
Alpha-glucosidase inhibitor:	Acarbose, Miglitol
Thiazolidinediones (TZD):	Pioglitazone, Rosiglitazone, Troglitazone
Meglitinides:	Nateglinide, Repaglinide, Mitiglinide
Dipeptidyl peptidase-4 (DPP-4) inhibitors:	Saxagliptin, Sitagliptin, Vildagliptin